Menu Search
Equities

Faron Pharmaceuticals Oy

FARN:LSE

Faron Pharmaceuticals Oy

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)143.75
  • Today's Change1.25 / 0.88%
  • Shares traded17.54k
  • 1 Year change-34.70%
  • Beta-0.0354
Data delayed at least 20 minutes, as of Nov 22 2024 14:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in EURView more

In 2023, Faron Pharmaceuticals Oy did not generate a significant amount of cash. Cash Flow from Financing totalled 23.98m or -- of revenues. In addition the company used 23.81m for operations while cash used for investing totalled 123.00k.
Cash flow per share-0.3104
Price/Cash flow per share--
Book value per share0.011
Tangible book value per share0.0023
More ▼

Balance sheet in EURView more

Faron Pharmaceuticals Oy appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. Faron Pharmaceuticals Oy has considerable financial risk.
Current ratio1.45
Quick ratio--
Total debt/total equity9.23
Total debt/total capital0.9022
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.